Compare ULBI & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ULBI | TLSI |
|---|---|---|
| Founded | 1990 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.1M | 270.2M |
| IPO Year | 1995 | 2020 |
| Metric | ULBI | TLSI |
|---|---|---|
| Price | $5.60 | $4.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 33.7K | ★ 107.2K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 13.00 | N/A |
| Revenue | ★ $191,159,000.00 | $45,151,000.00 |
| Revenue This Year | $20.00 | $35.45 |
| Revenue Next Year | N/A | $37.58 |
| P/E Ratio | $0.43 | ★ N/A |
| Revenue Growth | 16.24 | ★ 53.41 |
| 52 Week Low | $4.90 | $2.20 |
| 52 Week High | $8.25 | $7.95 |
| Indicator | ULBI | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 32.20 | 42.35 |
| Support Level | $5.54 | $4.21 |
| Resistance Level | $5.66 | $4.82 |
| Average True Range (ATR) | 0.26 | 0.29 |
| MACD | -0.14 | -0.08 |
| Stochastic Oscillator | 12.57 | 4.23 |
Ultralife Corp provides products and services ranging from power solutions to communications and electronics systems to customers across the globe in the government and defense, medical, safety and security, energy, and industrial sectors. The company also designs, manufactures, installs, and maintains power and communications systems including rechargeable and non-rechargeable batteries, charging systems, communications and electronics systems and accessories, and custom-engineered systems. The company's segments include Battery and Energy Products, and Communications Systems. It generates maximum revenue from the Battery and Energy Products segment, and from the U.S. The Battery & Energy Products segment includes Lithium 9-volt, cylindrical, and various other non-rechargeable batteries.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.